Combined PI3K Inhibitor and Eribulin Enhances Anti-Tumor Activity in Preclinical Models of Paclitaxel-Resistant, PIK3CA-Mutated Endometrial Cancer

SIMPLE SUMMARY: Paclitaxel-based chemotherapy is the standard front-line therapy for advanced or metastatic endometrial cancer. However, paclitaxel resistance eternally develops. Based on the high prevalence of PIK3CA mutation, reaching 50%, in endometrial cancer, we preclinically investigated the e...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeong, Yeong Gyu, Katuwal, Nar Bahadur, Kang, Min Sil, Ghosh, Mithun, Hong, Sa Deok, Park, Seong Min, Kim, Seul-Gi, Kim, Tae Hoen, Moon, Yong Wha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571568/
https://www.ncbi.nlm.nih.gov/pubmed/37835582
http://dx.doi.org/10.3390/cancers15194887

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571568/
https://www.ncbi.nlm.nih.gov/pubmed/37835582
http://dx.doi.org/10.3390/cancers15194887

Ejemplares similares